Jan 12, 2021
The US Food and Drug Administration (FDA) has published a final guidance document introducing the “Safer Technologies Program,” abbreviated as “STep." STeP is a voluntary program designed for specific medical devices that are expected to significantly improve the safety of currently available treatments or diagnostics for diseases and conditions considered less serious than those eligible for the Breakthrough Devices Program, after which STeP is modeled. Devices may be eligible for this program if they are subject to review under a premarket approval (PMA) application, De Novo request, or 510(k) premarket notification. A draft of this document was initially released in September 2019.
The guidance explains the guiding principles of STeP and provides a breakdown of the program’s acceptance and review policies. It also discusses the mechanisms that the FDA makes available for feedback on device development, including sprint discussion and data development plan (DDP) review. Appendix 1 outlines the recommended information that should be included in a Q-submission requesting inclusion in STeP. Accordingly, the agency’s guidance on the Q-Submission Program has been updated to include submissions related to STeP in the list of interactions being tracked in the Q-Sub program.
The FDA will be hosting a webinar on February 1, 2021 to summarize details about STeP and go over the contents of this guidance. Approval of requests for inclusion in STeP is to begin on March 8, 2021.
Further information and resources related to STeP can be found on the FDA Q&A page, Safer Technologies Program (STeP) for Medical Devices.
An updated guidance document extends the deadline for companies to deal with applications and submissions placed on hold during the COVID-19 pandemic, while virtual advisory committee meetings and additional alternatives to on-site MDSAP audits will be available.
The agency has published this document to clarify the two distinct review processes available to medical device manufacturers who have been denied a Certificate to Foreign Government (CFG) for a given product.
The Agency’s Center for Devices and Radiological Health (CDRH) will try using the Box filesharing service for submissions and is seeking to help manufacturers and stakeholders to incorporate Clinical Outcome Assessments and Patient Preference Information into their processes.
US FDA launches ASCA pilot to improve medical device premarket review processes